keyword
https://read.qxmd.com/read/38524010/eye-plaque-brachytherapy-for-choroidal-malignant-melanoma-a-case-report-on-the-use-of-innovative-technology-to-expand-access-improve-practice-and-enhance-outcomes
#1
Paul Mobit, Claus Chunli Yang, Mary R Nittala, Rui He, Hiba Z Ahmed, Gary Shultz, Albert Lin, Srinivasan Vijayakumar
Our institute established an eye plaque interstitial brachytherapy (EPIBT) program in 2007 using the Collaborative Ocular Melanoma Study (COMS) eye plaque. In this case report, we demonstrated an eye plaque treatment planned and executed using Eye Physics Plaque (Los Alamitos, CA) for a 72-year-old male patient with an extra-large tumor with a maximum width of 18.6 mm and height of 13.7 mm. The use of a customized eye plaque, manufactured through three-dimensional (3D) printing, has empowered us to plan and administer treatment for this patient with uveal melanoma...
February 2024: Curēus
https://read.qxmd.com/read/38522768/efficacy-and-safety-of-postoperative-adjuvant-radiotherapy-in-resected-nasal-cavity-and-paranasal-sinus-mucosal-melanoma-a-combined-analysis
#2
JOURNAL ARTICLE
Bin Lian, Yue Yang, Baomin Zheng, Lu Si, Li Zhou, ZhiHong Chi, Lili Mao, Xuan Wang, Siming Li, Juan Li, LiPing Wang, Jun Guo, Chuanliang Cui
BACKGROUND: Mucosal melanoma of the nasal cavity and paranasal sinuses (NPMM) is a highly aggressive disease. The role of postoperative adjuvant radiotherapy is controversial. METHODS: A total of 300 patients with NPMM treated between March 2009 and January 2020 were divided into SA (surgery alone, 158 patients) and SR (surgery plus radiotherapy, 142 patients) groups. Postoperative radiotherapy was recommended, with a total dose of 65-70 Gy/30-35 fx to the GTV (gross tumor volume) and 60 Gy/30 fractions to the CTV (clinical target volume)...
March 22, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38519492/fbxo22-promotes-glioblastoma-malignant-progression-by-mediating-vhl-ubiquitination-and-degradation
#3
JOURNAL ARTICLE
Zhigang Shen, Tao Dong, Hongmei Yong, Chuyin Deng, Changxiu Chen, Xintian Chen, Miaolei Chen, Sufang Chu, Junnian Zheng, Zhongwei Li, Jin Bai
Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite comprehensive treatment with traditional surgery, radiotherapy, and chemotherapy, the median survival rate is <14.6% and the 5-year survival rate is only 5%. FBXO22, a substrate receptor of the SCF ubiquitin ligases, has been reported to play a promoting role in melanoma, liver cancer, cervical cancer, and other cancers. However, the function of FBXO22 in GBM has not been reported. In the present study, we demonstrate that FBXO22 is highly expressed in glioma and is positively correlated with worse pathological features and shorter survival of GBM patients...
March 23, 2024: Cell Death Discovery
https://read.qxmd.com/read/38513311/twelve-years-after-the-french-national-network-on-rare-head-and-neck-tumours-refcor
#4
JOURNAL ARTICLE
Cassandre Gasne, Sarah Atallah, Etienne Dauzier, Juliette Thariat, Nicolas Fakhry, Benjamin Verillaud, Marion Classe, Sebastien Vergez, Antoine Moya-Plana, Valerie Costes-Martineau, Christian Righini, Ludovic de Gabory, Laurence Digue, Charles Dupin, François Régis Ferrand, Caroline Even, Bertrand Baujat
BACKGROUND: Rare cancers constitute less than 10% of head and neck cancers and lack sufficient evidence for standardized care. The French Rare Head and Neck Cancer Expert Network (REFCOR) as established a national database to collect data on these rare cancers. This study aims to describe patient and tumour characteristics in this database. METHODS: Prospective data collection was conducted across multiple centers. Survival analyses were performed using Kaplan Meier method and Log Rank test...
March 20, 2024: Oral Oncology
https://read.qxmd.com/read/38512416/head-and-neck-mucosal-melanoma-where-are-we-now
#5
REVIEW
Curtis Hanba, Ehab Hanna
PURPOSE OF REVIEW: To highlight recent and relevant treatment considerations while managing mucosal melanoma. RECENT FINDINGS: Evidence is building to support the use of targeted therapy and immunotherapy while managing mucosal melanoma. Surgical resection with postoperative radiotherapy plays a major role in managing resectable disease. Recent studies evaluate the addition of targeted, and immunotherapies with an attempt to determine the most efficacious sequence of treatment...
March 21, 2024: Current Oncology Reports
https://read.qxmd.com/read/38508783/are-we-ready-for-life-in-the-fast-lane-a-critical-review-of-preoperative-hypofractionated-radiotherapy-for-localized-soft-tissue-sarcoma
#6
REVIEW
B Ashleigh Guadagnolo, Elizabeth H Baldini
This critical review aims to summarize the relevant published data regarding hypofractionation regimens for preoperative radiation therapy (RT) prior to surgery for soft tissue sarcoma (STS) of the extremity or superficial trunk. We identified peer-reviewed publications using a PubMed search on the MeSH headings of "soft tissue sarcoma" AND "hypofractionated radiation therapy." To obtain complication data on similar anatomical radiotherapeutic scenarios we also searched "hypofractionated radiation therapy" AND "melanoma" as well as "hypofractionated radiation therapy" AND "breast cancer...
April 2024: Seminars in Radiation Oncology
https://read.qxmd.com/read/38505592/stereotactic-body-radiotherapy-as-a-viable-treatment-on-extracranial-oligometastases-in-melanoma-patients-a-retrospective-multicentric-study
#7
JOURNAL ARTICLE
Victorine Trentesaux, Sophie Maiezza, Emilie Bogart, Marie-Cécile Le Deley, Emmanuel Meyer, Ludovic Vanquin, David Pasquier, Laurent Mortier, Xavier Mirabel
INTRODUCTION: Stereotactic radiotherapy (SBRT) potentially has a role in the management of oligometastatic melanoma. However, literature with data specific to this management is very limited. The objectives of this study were to evaluate the time to local control (LC) of extra-cranial melanoma metastases after SBRT treatment and to help establish if SBRT is a useful therapy for oligometastatic melanoma. METHODS: A retrospective study was conducted with data collected from two referral centers in France between 2007 and 2020...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38504000/organ-specific-accuracy-of-18-f-fdg-pet-ct-in-identifying-immune-related-adverse-events-in-patients-with-high-risk-melanoma-treated-with-adjuvant-immune-checkpoint-inhibitor
#8
JOURNAL ARTICLE
Birte Molvik Gideonse, Magnus Birkeland, Mie Holm Vilstrup, Peter Grupe, Mohammad Naghavi-Behzad, Christina H Ruhlmann, Oke Gerke, Malene Grubbe Hildebrandt
PURPOSE: This study aimed to determine the organ-specific accuracy of [18 F]FDG-PET/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of irAEs within the first year after starting treatment. MATERIALS AND METHODS: This registry-based study included individuals who had undergone surgical removal of melanoma and were undergoing adjuvant ICI treatment (either nivolumab or pembrolizumab)...
March 20, 2024: Japanese Journal of Radiology
https://read.qxmd.com/read/38500872/benefit-recurrence-pattern-and-toxicity-to-adjuvant-anti-pd-1-monotherapy-varies-by-ethnicity-and-melanoma-subtype-an-international-multicenter-cohort-study
#9
JOURNAL ARTICLE
Xue Bai, Aleigha R Lawless, Juliane A Czapla, Stefanie C Gerstberger, Benjamin C Park, Seungyeon Jung, Rebecca Johnson, Naoya Yamazaki, Dai Ogata, Yoshiyasu Umeda, Caili Li, Jun Guo, Keith T Flaherty, Yasuhiro Nakamura, Kenjiro Namikawa, Georgina V Long, Alexander M Menzies, Douglas B Johnson, Ryan J Sullivan, Genevieve M Boland, Lu Si
BACKGROUND: Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in survival, recurrence pattern and toxicity to adjuvant PD-1 between different ethnicities and melanoma subtypes. OBJECTIVE: We performed a multicenter cohort study incorporating 6 independent institutions in Australia, China, Japan, and the United States. The primary outcomes were recurrence free survival (RFS) and overall survival (OS)...
June 2024: JAAD international
https://read.qxmd.com/read/38497054/combining-surgery-radiotherapy-and-topical-chemotherapy-to-prevent-primary-orbital-exenteration-for-atypical-caruncular-melanoma-a-case-report
#10
Cédric De Landsheer, Valentien Merlevede, Celine Jacobs, Jo Van Dorpe, Julie De Zaeytijd, Virginie G S Ninclaus, Dimitri Roels
INTRODUCTION: This case report demonstrates the possibility of successful eye and vision-sparing therapy for caruncular melanoma. CASE PRESENTATION: We present an atypical presentation of a caruncular melanoma. After excisional biopsy, residual flat conjunctival melanosis resolved using topical chemotherapy (5-fluorouracil), which was well tolerated. Relapse of the melanoma was treated with external beam radiotherapy, but the tumor grew despite treatment. Eighteen months after complete excision of the relapsed melanoma, the patient remains tumor-free while the eye and its function remain preserved...
2024: Case Reports in Ophthalmology
https://read.qxmd.com/read/38496632/radiation-and-anti-pd-l1-synergize-by-stimulating-a-stem-like-t-cell-population-in-the-tumor-draining-lymph-node
#11
Zachary Buchwald, Yang Shen, Erin Connolly, Meili Aiello, Chengjing Zhou, Prasanthi Chappa, Haorui Song, Patan Tippitak, Tarralyn Clark, Maria Cardenas, Nataliya Prokhnevska, Annapaola Mariniello, Meghana Pagadala, Vishal Dhere, Sarwish Rafiq, Aparna Kesarwala, Alexandre Orthwein, Susan Thomas, Mohammad Khan, J Brandon Dixon, Gregory B Lesinski, Michael Lowe, Haydn Kissick, David Yu, Chrystal Paulos, Nicole Schmitt
Radiotherapy (RT) and anti-PD-L1 synergize to enhance local and distant (abscopal) tumor control. However, clinical results in humans have been variable. With the goal of improving clinical outcomes, we investigated the underlying synergistic mechanism focusing on a CD8+ PD-1+ Tcf-1+ stem-like T cell subset in the tumor-draining lymph node (TdLN). Using murine melanoma models, we found that RT + anti-PD-L1 induces a novel differentiation program in the TdLN stem-like population which leads to their expansion and differentiation into effector cells within the tumor...
March 6, 2024: Research Square
https://read.qxmd.com/read/38494565/leg-lymphoedema-after-inguinal-and-ilio-inguinal-lymphadenectomy-for-melanoma-results-from-a-prospective-randomised-trial
#12
JOURNAL ARTICLE
T S Lee, I Li, B Peric, R P M Saw, J P Duprat, E Bertolli, J B Spillane, B L van Leeuwen, M Moncrieff, A Sommariva, C P Allan, J H W de Wilt, R Pritchard- Jones, J L C Geh, J R Howle, A J Spillane
BACKGROUND: The Evaluation of Groin Lymphadenectomy Extent for Melanoma (EAGLE FM) study sought to address the question of whether to perform inguinal (IL) or ilio-inguinal lymphadenectomy (I-IL) for patients with inguinal nodal metastatic melanoma who have no clinical or imaging evidence of pelvic disease. Primary outcome measure was disease-free survival at 5 years, and secondary endpoints included lymphoedema. METHODS: EAGLE FM was designed to recruit 634 patients but closed with 88 patients randomised because of slow recruitment and changes in melanoma management...
March 17, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38473430/current-and-emerging-radiotherapy-options-for-uveal-melanoma
#13
REVIEW
Oleksii Semeniuk, Esther Yu, Mark J Rivard
What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has flourished and many different approaches have been developed such as low-dose-rate sources using alternate low-energy photon-emitting radionuclides, different plaque designs and seed-loading techniques, high-dose-rate brachytherapy sources and applicators, and low- and high-dose-rate beta-emitting sources and applicators...
March 6, 2024: Cancers
https://read.qxmd.com/read/38455253/demographics-aspects-of-brain-and-spine-metastatic-melanoma-retrospective-analysis-in-a-single-third-level-center
#14
JOURNAL ARTICLE
Daniel Alejandro Vega-Moreno, Shunichiro Kuramitsu, Eguchi Kaoru, Kajita Yasukazu, Ulises García-González, Abraham Ibarra-de la Torre, Liliana Hernández-Hernández, Rosa María Vicuña-González, Martha Elena González-Jiménez
BACKGROUND: Melanoma metastases to the CNS rank third in frequency, just after lung and breast metastases. There is controversy regarding the factors predisposing to developing CNS metastases in patients with cutaneous melanoma and their survival with conventional treatments. METHODS: We carried out a retrospective analysis in a third-level hospital in Mexico to determine epidemiological aspects of melanoma metastases to the central nervous system, factors related to its appearance, clinical presentation, and survival in three treatment groups: surgery, radiotherapy, and conservative management...
April 2024: World neurosurgery: X
https://read.qxmd.com/read/38454124/polygenic-risk-scores-radiation-treatment-exposures-and-subsequent-cancer-risk-in-childhood-cancer-survivors
#15
JOURNAL ARTICLE
Todd M Gibson, Danielle M Karyadi, Stephen W Hartley, Michael A Arnold, Amy Berrington de Gonzalez, Miriam R Conces, Rebecca M Howell, Vidushi Kapoor, Wendy M Leisenring, Joseph P Neglia, Joshua N Sampson, Lucie M Turcotte, Stephen J Chanock, Gregory T Armstrong, Lindsay M Morton
Survivors of childhood cancer are at increased risk for subsequent cancers attributable to the late effects of radiotherapy and other treatment exposures; thus, further understanding of the impact of genetic predisposition on risk is needed. Combining genotype data for 11,220 5-year survivors from the Childhood Cancer Survivor Study and the St Jude Lifetime Cohort, we found that cancer-specific polygenic risk scores (PRSs) derived from general population, genome-wide association study, cancer loci identified survivors of European ancestry at increased risk of subsequent basal cell carcinoma (odds ratio per s...
March 7, 2024: Nature Medicine
https://read.qxmd.com/read/38450592/novosorb%C3%A2-biodegradable-temporising-matrix-btm-in-the-reconstruction-of-cutaneous-malignancies-in-a-major-cancer-centre-a-case-series
#16
JOURNAL ARTICLE
Maxim Devine, Mark Edmondson, Peter Gearing, Elizabeth Concannon, Michael Findlay, Richard Zinn, Angela Webb
BACKGROUND: Non-graftable or composite defect reconstruction represents a major challenge to the reconstructive surgeon, with many wounds requiring local flap or free microvascular tissue transfer approaches. The recent advent of synthetic skin substitutes such as Biodegradable Temporizing Matrix (BTM) have revolutionized the management of complex defects including those caused by burns, trauma and infection, with low-morbidity and low-complexity surgery. However, limited data exist supporting their use in cancer reconstruction in Australia...
March 7, 2024: ANZ Journal of Surgery
https://read.qxmd.com/read/38449655/global-research-landscape-and-trends-of-cancer-radiotherapy-plus-immunotherapy-a-bibliometric-analysis
#17
JOURNAL ARTICLE
Yanhao Liu, Xu Jiang, Yujuan Wu, Haiming Yu
The aim of this study was to present current research trends on the synergistic use of radiotherapy and immunotherapy (IRT) for cancer treatment. On March 1, 2023, we conducted a literature search for IRT papers using the Web of Science database. We extracted information and constructed two databases - the Core Database (CD) with 864 papers and Generalized Database (GD) with 6344 papers. A bibliometric analysis was performed to provide insights into the research landscape, to identify emerging trends and highly cited papers and journals in the field of IRT...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38439727/merkel-cell-carcinoma-of-unknown-primary-origin
#18
JOURNAL ARTICLE
Helena Francetić, Luka Simetić, Čedna Tomasović Lončarić, Daška Štulhofer Buzina, Romana Čeović
Merkel cell carcinoma (MCC) is a rare and highly aggressive primary cutaneous neuroendocrine carcinoma most often occurring in the elderly. Risk factors include chronic sun exposure and immunosuppression (1). MCC is associated with frequent recurrences and a high metastatic potential and mortality rate (1). It is the second most common cause of skin-cancer-related death after melanoma. At primary diagnosis with an apparent cutaneous tumor, loco-regional metastases are present in up to 30% of patients, and 6-12% have distant metastatic disease (2-3)...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38439628/primary-nasopharyngeal-melanoma-without-invasive-and-metastasis-a-rare-case-reports-and-literature-reviews
#19
JOURNAL ARTICLE
Jian-Jun Wang, Yao-Dong Huan, Hua Liu
Objective: Nasopharyngeal melanoma is a rare mucosal malignant melanoma with high recurrence rate, metastasis rate and vascular invasion rate. In this paper, we report a case of primary nasopharyngeal mucosal melanoma. Methods: A case of primary nasopharyngeal mucosal melanoma was reported, and its clinical symptoms, pathological characteristics, treatment and follow-up were described in detail. Results: This report describes a 59-year-old male patient with persistent nasal congestion and suspected malignant nasopharyngeal neoplasm...
March 4, 2024: Ear, Nose, & Throat Journal
https://read.qxmd.com/read/38437862/subdural-hematoma-due-to-dural-metastasis-a-systematic-review-on-frequency-clinical-characteristics-and-neurosurgical-management
#20
JOURNAL ARTICLE
Bhavya Pahwa, Anish Tayal, Atulya Chandra, Joe M Das
BACKGROUND:  Subdural hematoma (SDH) occasionally accompanies dural metastasis and is associated with high recurrence rate, significantly impacting patient morbidity and mortality. This systematic review aims to evaluate the characteristics, management options, and outcomes of patients with SDH associated with dural metastasis. METHODS:  A comprehensive search of the PubMed and Cochrane databases was conducted for English-language studies published from inception to March 20, 2023, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines...
March 4, 2024: Journal of Neurological Surgery. Part A, Central European Neurosurgery
keyword
keyword
160662
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.